Company
ONK Therapeutics
- Biotech
- Founded:
- 2015
- Location:
- Galway, Ireland
Description
ONK Therapeutics develops off-the-shelf, optimally engineered natural killer (NK) cell therapies combining CAR and TRAIL variant constructs to treat hematological malignancies and solid tumors for clinical and research use.
Related
Cleara BiotechCleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development…
CiMaasCiMaas develops immunotherapy products that expand and engineer natural killer (NK) cells for adoptive cell therapy and CAR‑NK applications…
OncomatryxOncomatryx targets the tumor microenvironment with stroma-focused antibody-drug conjugates, applying this approach to metastatic solid…
TILT BiotherapeuticsTILT Biotherapeutics develops oncolytic viral immunotherapies and engineered viral payloads to modify tumor microenvironments and enhance…
Betaglue® TherapeuticsBetaglue® Therapeutics develops localized radiotherapeutic platforms delivering radiation directly into solid tumors, producing precision…
CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
- Asgard TherapeuticsAsgard Therapeutics develops AT-108, an off-the-shelf gene therapy using direct cell reprogramming to activate professional…
NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
ThelperThelper develops antiviral antibody–drug conjugates that target a virally encoded biomarker abundantly expressed in aggressive, metastatic…